LOXL2 and End Stage Liver Disease: Two studies noted factors associated with liver-related clinical events in patients with compensated cirrhosis15 or NASH44; these included baseline (or lack of improvement in) fibrosis stage; higher baseline levels of hepatic collagen, lysyl oxidase like 2, bilirubin, international normalized ratio, and Model for End-Stage Liver Disease; lower baseline platelets; higher noninvasive tests (enhanced liver fibrosis, NAFLD fibrosis score [NFS], fibrosis-4, AST-to-platelet ratio index, FibroSure/FibroTest); and higher (or worsening/lack of improvement in) hepatic venous pressure gradient.